2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal Of Comparative Effectiveness Research 2015, 4: 327-340. PMID: 26274794, PMCID: PMC5549705, DOI: 10.2217/cer.15.20.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeMortality riskDeferasirox therapyOlder MDS patientsICD-9 codesIron chelation therapyEnd of studyMarginal structural modelsTransfusion thresholdMDS patientsMedicare patientsChelation therapyMedicare claimsMedicare populationPatientsBlood unitsAbstractTextTherapySignificant reductionSyndromeRiskWeeksMortality
2012
Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes
Zeidan A, Hendrick F, Friedmann E, Gore S, Baer M, Sasane M, Paley C, McNally D, Davidoff A. Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes. Blood 2012, 120: 426. DOI: 10.1182/blood.v120.21.426.426.Peer-Reviewed Original ResearchIron chelation therapyErythropoiesis-stimulating agentsMarginal structural modelsRisk of deathMyelodysplastic syndromeRenal diseaseTransfusion thresholdThyroid diseaseIron overloadChelation therapyObservation periodHealth statusOral iron chelation therapyICD-9-CM diagnosisICD-9-CM codesOlder MDS patientsSolid tumor diagnosisDuration of therapyCo-morbid conditionsOnset of diabetesEnd of studyOverall survival analysisPatients' health statusReduced mortality riskDrug side effectsUtilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.
Zeidan A, Baer M, Gore S, Sasane M, Paley C, McNally D, Davidoff A. Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D. Blood 2012, 120: 3178. DOI: 10.1182/blood.v120.21.3178.3178.Peer-Reviewed Original ResearchIron chelation therapyCongestive heart failureStudy cohortCardiac conduction disordersMedicare Part DTransfusion thresholdPerformance statusRed blood cellsMyelodysplastic syndromeRenal diseaseConduction disordersChelation therapyObservation periodHistory of CHFPart DCox proportional hazards modelICD-9-CM codesErythropoiesis-stimulating agentsCoronary artery diseaseEntire study cohortMyelodysplastic syndrome patientsEnd of studyProportional hazards modelUtilization patternsMedicare enrollment files